Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 16/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16216900 | 0.97 | MAP3K12 (0.53) | MAP3K12HRH4L3MBTL1 | |
| SCHEMBL16216902 | 0.82 | MAP3K12 (0.57) | MAP3K12HRH4 | |
| SCHEMBL16216903 | 0.79 | MAP3K12 (0.46) | MAP3K12HRH4 | |
| SCHEMBL16216901 | 0.79 | MAP3K12 (0.57) | MAP3K12HRH4 | |
| SCHEMBL16216911 | 0.78 | MAP3K12 (0.56) | MAP3K12HRH4 | |
| SCHEMBL16216898 | 0.78 | MAP3K12 (0.56) | MAP3K12HRH4 | |
| SCHEMBL20147243 | 0.77 | MAP3K12 (0.72) | MAP3K12 | |
| SCHEMBL16216899 | 0.73 | MAP3K12 (0.74) | MAP3K12 | |
| SCHEMBL16210214 | 0.72 | MAP3K12 (1.00) | MAP3K12 | |
| SCHEMBL856932 | 0.70 | MAP3K12 (0.48) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028954-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10010549-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180117044-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170239246-A9 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20160158234-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9266862-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140328805-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239246-A9 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, XDH | MAP3K12 2230/4885HRH4 347/4885L3MBTL1 2002/4885 |
| US-20180117044-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, XDH | MAP3K12 2230/4885HRH4 347/4885L3MBTL1 2002/4885 |
| US-10010549-B2 | Biheteroaryl compounds and uses thereof | BCHE, SNCA, HAX1 | MAP3K12 1980/4885HRH4 356/4885L3MBTL1 1843/4885 |
| US-20160158234-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, XDH | MAP3K12 2230/4885HRH4 347/4885L3MBTL1 2002/4885 |
| US-10028954-B2 | Biheteroaryl compounds and uses thereof | BCHE, SNCA, XDH | MAP3K12 2230/4885HRH4 347/4885L3MBTL1 2002/4885 |
| US-20180133219-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | MAP3K12 1980/4885HRH4 356/4885L3MBTL1 1843/4885 |
| US-20140328805-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, XDH | MAP3K12 2230/4885HRH4 347/4885L3MBTL1 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.